Scalper1 News
Biotech GlobeImmune (GBIM) said Wednesday that a hepatitis B drug it’s developing with Gilead Sciences (GILD) failed a midstage trial. GlobeImmune stock lost half its value, but Gilead stock rose. GlobeImmune said that GS-4774, a therapeutic vaccine that it licensed to Gilead, didn’t meet the trial’s primary endpoint of reducing the hepatitis B surface antigen (HBsAG) after 24 weeks of treatment, though GlobeImmune CEO Timothy Rodell said the Scalper1 News
Scalper1 News